Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VIPR2 | P41587 | 7/20 | 0.50 |
| ▸ | GLP1R | P43220 | 2/20 | 0.50 |
| ▸ | GCGR | P47871 | 1/20 | 0.50 |
| ▸ | GIPR | P48546 | 1/20 | 0.50 |
| ▸ | VIPR1 | P32241 | 5/20 | 0.48 |
| ▸ | BACE1 | P56817 | 3/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | CCKBR | P32239 | 1/20 | 0.43 |
| ▸ | PTH1R | Q03431 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30262014 | 0.91 | RXFP1 (0.47) | VIPR2GLP1RGCGRGIPRVIPR1 | |
| SCHEMBL30512750 | 0.91 | GLP1R (0.46) | VIPR2GLP1RGCGRGIPRVIPR1 | |
| SCHEMBL31157682 | 0.90 | VIPR2 (0.43) | VIPR2GLP1RGCGRGIPRVIPR1 | |
| SCHEMBL30140929 | 0.90 | BACE1 (0.49) | GLP1RGCGRGIPRVIPR1BACE1 | |
| SCHEMBL31157765 | 0.89 | PTPN1 (0.41) | VIPR2GLP1RGCGRGIPRVIPR1 | |
| SCHEMBL29453337 | 0.89 | VIPR2 (0.54) | VIPR2VIPR1BACE1 | |
| SCHEMBL29742723 | 0.89 | VIPR2 (0.49) | VIPR2GLP1RGCGRGIPRVIPR1 | |
| SCHEMBL31689336 | 0.89 | BACE1 (0.45) | VIPR2GLP1RGCGRGIPRVIPR1 | |
| SCHEMBL31157748 | 0.89 | IL23R (0.45) | VIPR2GLP1RGCGRGIPRVIPR1 | |
| SCHEMBL29453350 | 0.88 | VIPR2 (0.54) | VIPR2VIPR1BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220112510-A1 | METHODS AND COMPOSITION FOR TRANSFERRING T-DNA INTO A PLANT | PURDUE RESEARCH FOUNDATION (US) | 2022-04-14 | — | — | US | claimed |
| US-12509696-B2 | Methods and composition for transferring T-DNA into a plant | PURDUE RESEARCH FOUNDATION (US) | 2025-12-30 | — | — | US | disclosed |
| US-20240263186-A1 | EXPRESSION CONSTRUCTS, VIRD2 MUTANT AGROBACTERIUM STRAINS, AND METHODS OF USE THEREOF | PURDUE RESEARCH FOUNDATION | 2024-08-08 | — | — | US | disclosed |
| US-20220112510-A1 | METHODS AND COMPOSITION FOR TRANSFERRING T-DNA INTO A PLANT | PURDUE RESEARCH FOUNDATION (US) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12509696-B2 | Methods and composition for transferring T-DNA into a plant | AMPD2, MYB, TOMM22 | VIPR2 668/4885GLP1R 3909/4885GCGR 4592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.